6December - 2021EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comIn the past, pharmaceutical organizations chose to support an internal R&D drug discovery process while outsourcing only limited services such as routine or commodity-based activities and clinical trials. However, increasingly restrictive federal regulations have incited the need for more time, effort, and cost to bring new drugs to market. This has made the outsourcing of early-stage R&D more significant to pharmaceutical businesses. Additionally, it's positively affected contract development and manufacturing organizations (CDMOs) who are seeing a greater demand for a broader range of outsourced services to plug the gaps in their customers' in-house capacity. Many CDMOs are slowly expanding their offering to become full-service providers that offer a wider variety of capabilities to remain competitive. There is also an increased focus on developing `true partnerships' with CDMOs that can provide many services.The future of the CDMO landscape is achieving full onsite vertical integration-from early development through commercial manufacturing and everything in between. By vertically integrating all services at one site, modern CDMOs can help build and maintain long-term relationships between all multidisciplinary experts, creating an efficient and highly effective approach to pharmaceutical development. In this edition of Pharma Tech Outlook, we bring you the story of some of the most successful pharma outsourcing firms that are delivering the best solutions and services for their clients. This edition also offers a combination of thought leadership from subject matter experts with real-life stories on fostering robust partnerships and exclusive insights from CXOs. We hope this edition will provide you with the right assistance in choosing the partner that best fits your pharmaceutical requirements.Let us know your thoughts!A Paradigm Shift in Outsourcing RelationshipsCopyright © 2021 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.DECEMBER - 2021, Vol 07 - Issue 18 (ISSN 2644-2787) Published by ValleyMedia Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comsales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:
< Page 5 | Page 7 >